Valeria Mondelli, Graham Blackman, Matthew J Kempton, Thomas A Pollak, Conrad Iyegbe, Lucia R Valmaggia, Paul Amminger, Neus Barrantes-Vidal, Rodrigo Bressan, Mark van der Gaag, Lieuwe de Haan, Marie-Odile Krebs, Merete Nordentoft, Stephan Ruhrmann, Anita Riecher-Rössler, Bart P F Rutten, Gabriele Sachs, Nikolaos Koutsouleris, Philip McGuire
Individuals at clinical high risk (CHR) for psychosis have been found to have altered cytokine levels, but whether these changes are related to clinical outcomes remains unclear. We addressed this issue by measuring serum levels of 20 immune markers in 325 participants (n=269 CHR, n=56 healthy controls) using multiplex immunoassays, and then followed up the CHR sample to determine their clinical outcomes. Among 269 CHR individuals, 50 (18.6%) developed psychosis by two years. Univariate and machine learning techniques were used to compare levels of inflammatory markers in CHR subjects and healthy controls, and in CHR subjects who had (CHR-t), or had not (CHR-nt) transitioned to psychosis...
March 18, 2023: Brain, Behavior, and Immunity